I'd like to apologize right up front. This is an article that is heavy on numbers, focused on some mundane issues, and is really an academic exercise in how to analyze a turnaround. The good news: the company I am focusing on may be able to deliver 200% to 300% returns for the patient … [visit site to read . . . → Read More: This Could be a Home-Run Stock